AI Article Synopsis
- The study evaluated the effectiveness of 0.01% atropine eye drops in slowing down myopia progression in young patients over a 4-year period.
- A total of 2,387 patients were involved, showing a significant reduction in myopia progression in the treated group compared to a control group, with results apparent as early as the first follow-up.
- The findings support existing literature, confirming that atropine is an effective treatment for slowing myopia without major side effects.
Article Abstract
Purpose: To assess the effectiveness of atropine 0.01% in slowing the progression of myopia in young patients.
Methods: 2,387 patients with progressive myopia (more than -0.50 spherical diopters ‹D› increased in the last year) were enrolled. They received, every evening, one drop of atropine 0.01% in each eye. Refraction was then measured at baseline (T0) and once a year (T1, T2, T3, T4) for a 4-years follow-up period, and compared with a non-treated control group.
Results: A reduction in the myopic progression was observed in the treated group respect to the control one. The average spherical refraction after 4 years increased by 27.06% in the treated group versus 241% of the control one. The difference in spherical increase between the two groups respect to time 0 was appreciable already at the first control, (T1 -T0, -0.21D vs. -1D) and continued to increase for all the 4-years follow-up period (T2-T0, -0.38D vs. -1.91D;T3-T0, -0.52D vs. -2.74D; T4-T0, -0.73D vs. -3.63D, respectively). It was always significant (P<0.01). Compared to the previous year, the average spherical increase was quite stable in the two groups (0.17 vs. 0.87, respectively). No significant tachyphylaxis or adverse effects were observed throughout the examination period.
Conclusions: 0.01% atropine was effective in slowing the progression of myopia in the treated group vs. control one. The clinical effect was noticeable already from the first control, and continued for all the observation period. The results of this study agree with those already reported in literature, and confirm the validity of this treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7417/CT.2024.5129 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Longitudinal Changes of Retinal Nerve Fiber Layer and Ganglion Cell-Inner Plexiform Layer in Highly Myopic Glaucoma: A 3-year Cohort Study.
Ophthalmology
January 2025
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangdong Provincial Clinical Research Center for Ocular Diseases, Guangzhou 510623, China. Electronic address:
Purpose: To describe the longitudinal changes in peripapillary retinal nerve fiber layer (pRNFL) and macular ganglion cell-inner plexiform layer (mGC-IPL) thicknesses in highly myopic eyes with and without glaucoma, and to investigate the effects of high myopia (HM) on the sectoral patterns of pRNFL and mGC-IPL thinning.
Design: Longitudinal cohort study.
Participants: A total of 243 eyes from 243 individuals with 3-year follow-up were included in this study: 109 eyes in the HM group, 64 eyes in the open-angle glaucoma (OAG) group and 70 eyes in the highly myopic glaucoma (HMG) group.
Analysis of the correlations between changes in posterior segment and anterior chamber segment after implantable collamer lens implantation in highly myopic patients.
BMC Ophthalmol
January 2025
Department of Refractive Surgery, Guangzhou Aier Eye Hospital, Jinan University, Guangzhou City, Guangdong Province, 510000, China.
Purpose: To evaluate the impact of Implantable Collamer Lens (ICL) implantation on anterior chamber angle parameters and posterior segment structures in highly myopic eyes and explore potential correlations between these changes. The study aimed to assess alterations in superficial and deep vessel density (SVD, DVD), foveal avascular zone (FAZ) area, and retinal nerve fiber layer (RNFL) thickness to clarify the safety profile of ICL implantation.
Methods: Prospective observational study, included 36 highly myopic eyes undergoing ICL implantation in surgery group and 23 non-surgical control eyes in non-surgery group.
Transformative Gamified Binocular Therapy for Unilateral Amblyopia in Young Children: Pilot Prospective Efficacy and Safety Study.
JMIR Serious Games
January 2025
Department of Ophthalmology, Eye and ENT Hospital of Fudan University, No.83 Fenyang Road, Xuhui District, Shanghai, 200031, China, 86 021-64377134.
Background: Amblyopia is a common cause of visual impairment in children. Compliance with traditional treatments for amblyopia is challenging due to negative psychosocial impacts. Recent shifts in amblyopia treatment have moved from suppressing the dominant eye to enhancing binocular visual function.
View Article and Find Full Text PDFUnderstanding cataract development in axial myopia: The contribution of oxidative stress and related pathways.
Redox Biol
January 2025
Department of Ophthalmology, Kornel Gibiński University Clinical Center, Medical University of Silesia, Katowice, Poland; Department of Ophthalmology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland; GlaucoTech Co, Katowice, Poland.
Myopia is an evolving global health challenge, with estimates suggesting that by 2050 it will affect half of the world's population, becoming the leading cause of irreversible vision loss. Moreover, myopia can lead to various complications, including the earlier onset of cataracts. Given the progressive aging of the population and the increase in life expectancy, this will contribute to a rising demand for cataract surgery, posing an additional challenge for healthcare systems.
View Article and Find Full Text PDFExperimental Evaluation of Ocular Rigidity and Pressure-Volume Relationship After Ex-Vivo Scleral Cross-Linking With Riboflavin and Ultraviolet A in Porcine Eyes.
Cureus
December 2024
Ophthalmology, Medical School, Institute of Vision and Optics, University of Crete, Heraklion, GRC.
Purpose: Scleral cross-linking (SXL) with ultraviolet A (UVA) and riboflavin has already been used in laboratory studies for scleral stiffness increase as a potential treatment for progressive myopia and scleral ectasia. This study aims to investigate whether the regional application of scleral cross-linking (SXL) with ultraviolet A (UVA) and riboflavin in fresh porcine eye globes affects the ocular rigidity as well as its impact on intraocular pressure after an induced acute increase in the volume of intraocular fluid.
Methods: The study included two groups of fresh porcine eyes: an experimental group (n=20) that underwent scleral cross-linking (SXL) with riboflavin and UVA applied to the posterior sclera and a control group (n=20) that did not receive SXL treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!